Please login to the form below

Not currently logged in
Email:
Password:

Bayer says it has financial muscle for larger acquisitions

The CEO of Bayer says the company has the financial clout to pursue a 'larger' acquisition than that of its 2006 purchase of Schering AG

The CEO of German-headquartered Bayer, Werner Wenning, has said that the company has the financial clout to pursue a 'larger' acquisition than that of its 2006 purchase of Schering AG (now Bayer Schering Pharma AG).

Wenning told the German newspaper Handelsblatt that the company had cut debt by EUR 4.8bn in 2007, but added that Bayer's current focus was on integrating Schering before making any further moves.

Any potential takeover would be in the healthcare industry and would not necessarily be a "big bang", added Wenning.

Wenning revealed that the company's drugs division will post internal growth at the same rate as the industry through 2009, but should grow faster than the market thereafter on demand for anti-thrombosis pill Xarelto (rivaroxaban) and cancer drug Nexavar (sorafenib).

Sales in Q3 FY07 at Bayer grew 4.5 per cent to reach EUR 7.8bn, compared with Q3 FY06 sales of EUR 7.5bn. The company's total business expanded by seven per cent in the same time period, while group net income was EUR 1.2bn after a one-time positive tax effect.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Article: What's next? How behavioural science can support pharma's future
...

Infographics